Cybin engages thermo fisher scientific to provide u.s.-based manufacturing for its cyb003 program for the adjunctive treatment of major depressive disorder

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it has engaged thermo fisher scientific (“thermo fisher”), the world leader in serving science, to support the phase 3 clinical supply and potential commercial manufacturing of cyb003, the company's proprieta.
CYBN Ratings Summary
CYBN Quant Ranking